Stifel initiates Guardant Health [GH] at Buy and sets price target at $175

CYTO Stock

Stifel launched its Guardant Health [GH] rating to the equivalent of Buy and assigned the price target of $175.0, in a research note dated 2021-01-11. That figure represents around a 22.49% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with BTIG Research’s analysts assigning the shares to […]

Market Globalist
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.